Zacks Research Issues Negative Forecast for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Stock analysts at Zacks Research lowered their Q2 2025 earnings per share (EPS) estimates for Agilent Technologies in a report issued on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings of $1.26 per share for the quarter, down from their prior estimate of $1.33. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.57 per share. Zacks Research also issued estimates for Agilent Technologies’ Q4 2025 earnings at $1.58 EPS, Q3 2026 earnings at $1.53 EPS, Q4 2026 earnings at $1.65 EPS, FY2026 earnings at $6.03 EPS, Q1 2027 earnings at $1.61 EPS and FY2027 earnings at $6.61 EPS.

A has been the topic of several other research reports. Wells Fargo & Company decreased their price target on shares of Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a research report on Monday, December 9th. StockNews.com upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, December 24th. Barclays upgraded shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and lifted their price target for the stock from $135.00 to $145.00 in a research report on Monday, February 10th. Citigroup lifted their price target on shares of Agilent Technologies to $165.00 and gave the stock a “buy” rating in a research report on Thursday, December 19th. Finally, Bank of America decreased their price target on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $146.15.

Agilent Technologies Trading Up 0.4 %

Agilent Technologies stock opened at $120.72 on Friday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. The firm has a market cap of $34.42 billion, a price-to-earnings ratio of 27.75, a price-to-earnings-growth ratio of 3.38 and a beta of 1.11. Agilent Technologies has a 1 year low of $117.17 and a 1 year high of $155.35. The firm’s 50 day moving average price is $136.74 and its two-hundred day moving average price is $137.29.

Agilent Technologies (NYSE:A) last announced its earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, topping the consensus estimate of $1.27 by $0.04. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. The firm had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.67 billion.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of A. Quest Partners LLC lifted its position in Agilent Technologies by 339.3% during the 3rd quarter. Quest Partners LLC now owns 6,862 shares of the medical research company’s stock worth $1,019,000 after acquiring an additional 5,300 shares during the last quarter. Prospera Financial Services Inc acquired a new position in Agilent Technologies during the 3rd quarter worth $375,000. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of Agilent Technologies during the 3rd quarter worth about $2,331,000. Prospera Private Wealth LLC bought a new position in shares of Agilent Technologies during the 3rd quarter worth about $107,000. Finally, Jennison Associates LLC increased its holdings in shares of Agilent Technologies by 63.3% during the 3rd quarter. Jennison Associates LLC now owns 586,439 shares of the medical research company’s stock worth $87,075,000 after purchasing an additional 227,431 shares during the period.

Insider Activity

In related news, VP Rodney Gonsalves sold 1,908 shares of Agilent Technologies stock in a transaction on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the sale, the vice president now owns 21,786 shares of the company’s stock, valued at approximately $2,657,456.28. The trade was a 8.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total transaction of $286,650.00. Following the completion of the sale, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. The trade was a 4.60 % decrease in their position. The disclosure for this sale can be found here.

Agilent Technologies Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st will be issued a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a dividend yield of 0.82%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies’s dividend payout ratio is currently 22.76%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.